August 31, 2018
Exicure raises a $22,000,000 venture round.
September 27, 2017
Exicure raises a $20,000,000 venture round from AbbVie Biotech Ventures, Craig Mundie, David R. Walt, Katalyst Securities, Mark Tompkins, Patrick G. Ryan and Tempus Labs.
September 6, 2017
Exicure raises a $11,200,000 venture round from Alumni Ventures Group, HT Capital, Knoll Capital Management and Luye Pharma.
June 17, 2017
Exicure raises a $13,600,000 series C round from Bill Gates, Boon Hwee Koh, Craig Mundie and Patrick Ryan.
October 21, 2015
Exicure raises a $14,800,000 venture round from Liz Lefkofsky and Tempus Labs.
February 5, 2015
Exicure raises a $4,500,000 series C round.
December 21, 2011
Exicure raises a $5,400,000 series B round from Abbott Biotech Ventures, Craig Mundie, David R. Walt, Eric Schmidt and Patrick Ryan.
December 1, 2009
Exicure raises a $2,500,000 series A round.
Documentaries, videos and podcasts
May 13, 2021
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNATM) technology, today announced the appointment of Brian C. Bock as the Company's Chief Financial Officer (CFO) effective immediately.